Clinical Trial: A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer

U.S., April 9 -- ClinicalTrials.gov registry received information related to the study (NCT07518173) titled 'A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer' on April 02.

Brief Summary: This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M07D1 combined with Pertuzumab versus docetaxel plus Trastuzumab and Pertuzumab in patients with first-line HER2-positive recurrent or metastatic breast cancer.

Study Start Date: April, 2026

Study Type: INTERVENTIONAL

Condition: HER2-positive Breast Cancer

Intervention: DRUG: BL-M07D1

Administration by ...